Simple Man

Be nice. Be kind. Be content

[Simple Man @Simple_4_Life]

$NUVB

https://t.co/SyTjnoQkFU

[Simple Man @Simple_4_Life]

* **Director John Richard Sylvester (November 21, 2025):** Purchased 4,386 shares at $8.89 per share, totaling $38,991.
* **CEO Gerard J. Michel (November 11, 2025):** Purchased 11,500 shares at $8.53 per share, totaling $98,049.

[Simple Man @Simple_4_Life]

$DCTH insiders’ purchases, per Gemini:
* **CEO Gerard J. Michel (March 2, 2026):** Purchased 11,200 shares at $8.96 per share, totaling $100,352.
* **CFO Sandra Pennell (March 6, 2026):** Purchased 5,533 shares at $9.04 per share, totaling $50,018.

[Simple Man @Simple_4_Life]

$MIST Per Claude — “PBMs like OptumRx and Caremark typically update their formularies on January 1 and July 1 each year, so July 1, 2026 would be the next natural opportunity for either to add Cardamyst…”

I have the rest of this month to accumulate more MIST.

[Simple Man @Simple_4_Life]

$MIST Waiting patiently for some positive news regarding CVS Caremark and UNH OptumRx. I believe it’s just a matter of time.

[Simple Man @Simple_4_Life]

Is Hepzato Kit a true medical monopoly?

$DCTH Hepzato Kit is the 1st & only FDA-approved whole-liver directed therapy. Its unique "isolate & filter" tech floods the liver with high-dose chemo while shielding the rest of the body.

Does DCTH have aasymmetric growth potential?

[Simple Man @Simple_4_Life]

@alex__pitti $ADBE ‘s PEG is 0.69 which Peter Lynch would consider as a bargain. I thought of trimming $UNH to get $ADBE but chose not to because software is facing strong AI headwinds and probably will be for a while longer. Best of luck to you.

[Simple Man @Simple_4_Life]

@alex__pitti Excellent video explaining the mechanism of PVST in details. If you’re only interested in Cardamyst, it starts at minute mark 22:00.

Personally, after watching this video, I feel more confident holding $MIST in my portfolio. Watch the video and see what you think.

[Simple Man @Simple_4_Life]

@WallStSai Looking like it’s an open season for pharmaceutical / MedTech M&A.

Are $NUVB $DCTH $MIST on the radar somewhere? All three have commercialized FDA approved products.

[Simple Man @Simple_4_Life]

@alex__pitti What do you think was the catalyst for the recent volume spike? Investors seemed to rushed in to load up on $DCTH , as evidenced by the increase in share price.

[Simple Man @Simple_4_Life]

Per Gemini: Delcath Systems $DCTH has only 35.31M shares outstanding.

Institutions hold a dominant 51.56% majority (led by Rosalind Advisors, BlackRock & Vanguard), insiders own a lean 3.00%,

The remaining 45.44% makes up the active public float. (About 16M to 17M shares)

[Simple Man @Simple_4_Life]

$MIST
Getting $CVS Caremark and $UNH OptumRx onboard is just a matter of time, in my lay person / MIST biased investor’s opinion.

[Simple Man @Simple_4_Life]

$DCTH

This represents a surge of 250% to 300% above its historical daily average, and a massive increase over the dry volume seen just a couple of weeks prior.

Is there something afoot? Massive volume spike accompanied by higher share price looked like someone knows something.

[Simple Man @Simple_4_Life]

Per Gemini:
$DCTH This Week's Surge: Volume exploded significantly, breaching 842,000 shares in a single session and scaling up to a peak of 1.20 million shares on high-activity days.

This represents a surge of 250% to 300% above its historical daily average…

[Simple Man @Simple_4_Life]

@alex__pitti 2026 might be a pivotal year for DCTH. We have 6 months to see how it will pan out.

[Simple Man @Simple_4_Life]

@alex__pitti High tides lift all boats!
With $GSK in talks to acquire $NUVL for $9B, that certainly might make the forerunner in ROS1+ NSCLC $NUVB become more valuable, in my opinion. What are your thoughts?

[Simple Man @Simple_4_Life]

@alex__pitti I agreed. I started doing research on $MIST when I heard of Cardamyst, the only medication / nasal spray to instantly help PSVT patients lower their heart rates. I bought in early but it’s alright. Added 50% more today at $1.23. I’ll ride this $MIST $DCTH train with you 🍺🍺

[Simple Man @Simple_4_Life]

Scarcity Premium: With $NUVL off the board, left-behind Big Pharma buyers needing a lung cancer foothold will pivot to $NUVB as the premier remaining independent target.

[Simple Man @Simple_4_Life]

Per Gemini:

Nuvation Bio $NUVB can ride the $9B GSK/NUVL wave via three rapid catalysts:
Valuation Spike: A $9B benchmark for NUVL forces Wall Street to re-rate NUVB upward, closing the massive pricing gap on an already-approved, revenue-generating asset.

[Simple Man @Simple_4_Life]

Commercial Head Start: $NUVL’s drug faces a September 2026 PDUFA date. $NUVB can exploit this multi-month launch runway to lock down crucial front-line market share for Ibtrozi.

[Simple Man @Simple_4_Life]

@alex__pitti 🍺🍺